Table 2 Multivariable analyses of associations between patient characteristics and overall survival
Characteristic | Category | FOLFOX (5-FU dose intensity) (n = 371) | CAPOX (Capecitabine dose intensity) (n = 164) | All patients (Oxaliplatin dose intensity) (n = 526) | |||
|---|---|---|---|---|---|---|---|
Hazard Ratio (95% Confidence Interval) | P value | Hazard Ratio (95% Confidence Interval) | P value | Hazard Ratio (95% Confidence Interval) | P value | ||
Age at chemo start | 0.99 (0.97 to 1.02) | 0.62 | 1.01 (0.96 to 1.06) | 0.70 | 1.00 (0.98 to 1.02) | 0.95 | |
Sex | Female | Reference | 0.59 | Reference | 0.18 | Reference | 0.46 |
Male | 1.13 (0.71 to 1.80) | 2.05 (0.73 to 5.77) | 1.17 (0.77 to 1.77) | ||||
Dose intensity | ≤ 80% | Reference | 0.03 | Reference | 0.006 | Reference | 0.005 |
> 80% | 0.56 (0.33 to 0.94) | 0.23 (0.08 to 0.65) | 0.52 (0.33 to 0.82) | ||||
T stage | T0-T2 | Reference | 0.03 | – | – | Reference | < 0.001 |
T3 | 1.47 (0.58 to 3.75) | – | – | 1.66 (0.65 to 4.19) | |||
T4 | 2.56 (1 to 6.6) | – | – | 3.33 (1.32 to 8.41) | |||
N stage | N0 | Reference | < 0.001 | Reference | 0.03 | Reference | < 0.001 |
N1 | 7.20 (0.96 to 53.72) | 1.44 (0.16 to 13.05) | 7.55 (1.03 to 55.51) | ||||
N2 | 20.70 (2.79 to 153.3) | 4.70 (0.57 to 38.85) | 19.72 (2.71 to 143.54) | ||||